Pharos iBio Co., Ltd. develops treatments for rare and refractory diseases using AI based drug development platform in South Korea. It develops PHI-101-AML that is in phase 1 clinical trial for the treatment of refractory/recurrent acute myelogenous leukemia (AML); PHI-101-OC that is in phase 1 clinical trial for the treatment of platinum-resistant/refractory ovarian cancer; PHI-101-TNBC for the treatment of metastatic triple-negative breast cancer; PHI-101-RS, a radiation sensitizer; PHI-201, a K-Ras hub-protein inhibitor; PHI-301, a FAK hub-protein inhibitor for the treatment of metastatic cancer; PHI-401, an anaplastic lymphoma kinase (ALK) protein inhibitor; and PHI-501 a pan-RAF/DDRs inhibitor. The company was founded in 2016 and is headquartered in Anyang-Si, South Korea.
Metrics to compare | 388870 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship388870PeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.0x | −4.1x | −0.6x | |
PEG Ratio | −2.99 | −0.11 | 0.00 | |
Price/Book | 4.9x | 2.7x | 2.6x | |
Price / LTM Sales | - | 5.0x | 3.4x | |
Upside (Analyst Target) | - | 0.0% | 39.1% | |
Fair Value Upside | Unlock | 21.1% | 5.4% | Unlock |